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Abstract: Oral bisphosphonates are of proven efficacy in preventing fractures in postmenopausal 
osteoporosis. However, poor adherence limits their real-world efficacy and clinical utility. 
Zoledronic acid (ZOL) is a potent bisphosphonate administered by annual intravenous infusion, 
effectively ensuring adherence to therapy over the following year. According to available data, 
66% to 79% of patients have expressed a preference for ZOL over oral bisphosphonates. This 
is likely to lead to enhanced clinical outcomes, although long-term (repeat annual) adherence 
is currently unknown. ZOL is of proven efficacy, with hip fracture reduction of 41% and 
morphometric vertebral fracture reduction of 70% over 3 years in the HORIZON PFT trial. 
It has demonstrated a good side-effect profile with postinfusion flu-like symptoms being 
the most common. Additionally, it has been associated with decreased mortality in patients 
following surgery for hip fracture. There is no clear association between exposure and the rate 
of serious or nonserious atrial fibrillation. We review adherence to oral bisphosphonates, and 
the pharmacokinetics, efficacy, safety, and patient preference for ZOL.
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Introduction
Postmenopausal osteoporosis (PMO) is a chronic condition characterized by decreased 
bone mass and increased risk of fragility fracture. Such fractures lead to pain, disability, 
impaired quality of life, increased risk of death, and annual health-care costs in the United 
States of at least US$19 billion (2005 figures).1 The average woman and man older than 
50 years have a 50% and 25% risk of osteoporotic fracture in their remaining lifetime 
respectively.1 Worldwide, there were an estimated 1.66 million hip fractures in 19902 – a 
number that is likely increasing with an aging population. Additionally, hip fractures cause 
more total days of disability than any other clinical osteoporotic fracture.3 Compounding 
this, 20% to 24% of patients die within the first year following hip fracture, and only half 
of survivors regain full independence.4 Therefore, timely diagnosis, provision of effective 
therapy and adherence to therapy are of paramount importance.
Like other chronic diseases though, particularly asymptomatic ones, compliance 
and persistence (collectively called “adherence”) with PMO therapy are abysmal. In 
one longitudinal cohort study, 68% of patients on a daily bisphosphonate regimen and 
56% on a weekly regimen had discontinued therapy at 1 year. 5 Data from a United 
Kingdom database showed that at 1 year 42% had discontinued bisphosphonates, and 
76% had done so by 5 years.6 In another study,7 47% of patients at 6 months and 54% 
at 1 year had suboptimal adherence (medication possession ratio [MPR]  80%), with 
similar trends in other studies.Patient Preference and Adherence 2009:3 190
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Unfortunately, the best drug will not work in the patient 
who does not use it. Although oral bisphosphonates have 
confirmed efficacy in reducing fragility fractures, poor 
adherence limits their clinical utility and negatively impacts 
on outcomes. Data from two US claims databases showed 
that adherence (MPR  80%) reduced nonvertebral fracture 
risk by 20%, and hip fracture risk by 45% (P  0.001 for 
both).8 Adherence levels 50% did not have any effect on 
fracture risk, but risk decreased as adherence increased above 
50%, with a steep improvement between 75% and 100%. The 
aforementioned UK study showed no fracture risk reduction 
in those receiving less than 6 months of therapy.6 These data 
suggest maximal benefit with maximum adherence. They also 
suggest that even with some degree of drug use, suboptimal 
adherence can lead to a total loss of any benefit.
Although several studies of adherence to PMO therapy 
have found significant differences between adherent and 
nonadherent patients, attempts to develop a predictive model 
have been unsuccessful.9 Nonadherence to oral bisphospho-
nates is partly due to the frequency of dosing, inconvenience 
of administration requiring a fasting state pre-/postingestion, 
and gastrointestinal side-effects.10 Less frequent dosing with 
weekly and monthly oral regimens are generally preferred 
by patients over daily dosing, but are still associated with 
suboptimal adherence.11 In one study, younger age, female 
sex, fewer comorbid conditions, fewer PMO medication, 
and bone mineral density (BMD) testing each independently 
predicted compliance, but models accounted for only 6% 
of the variation seen.12 Surprisingly, associations of prior 
fracture with adherence have been inconsistent.
Intravenous  (IV)  zoledronic  acid  (ZOL),  5 mg 
administered annually, provides the greatest extended 
dosing interval, and reduces concerns about oral adminis-
tration, gastrointestinal intolerance and bioavailability. In 
two separate trials of outpatients comparing weekly oral 
alendronate to annual ZOL, 66% and 79% preferred the 
latter.13,14 While not all patients may comply with ZOL, and 
little is known about long-term adherence, it does essentially 
provide 100% adherence in the year following administration 
in those who choose to receive it.
Pharmacology and kinetics
Preclinical data indicate that ZOL, a nitrogen-containing 
bisphosphonate, is one of the most potent bisphosphonates 
available. It has a higher binding affinity for hydroxyapatite 
and is a more potent inhibitor of farnesyl disphosphonate 
synthase and bone resorption than other bisphosphonates.15 
ZOL has demonstrated inhibition of bone resorption in vivo 
at doses of 0.072 µg/kg.15 Dynamic bone histomorphometry 
has been evaluated in 93 patients with PMO. Results showed 
normal quality bone, preservation of trabecular architecture, 
with no evidence of impaired remodelling or mineralization 
defects.16
Pharmacokinetic data are not available for PMO. When 
assessed in 64 cancer patients, however, postinfusion decline 
in ZOL plasma concentrations showed a triphasic process, 
with a rapid decrease in the first 24 hours, and prolonged 
terminal elimination phase.16 An average of 39 ± 16% (± SD) 
was excreted in urine within the first 24 hours, with only trace 
amounts after 48 hours. The balance of drug, presumably 
bound to bone, is slowly released back into the systemic 
circulation, giving rise to the observed prolonged low plasma 
concentrations. ZOL is not recommended for patients with 
severe renal impairment (CrCl 30 mL/min) due to lack 
of experience in this population. No dosage adjustment is 
required with a CrCl 30 mL/min.16 ZOL is not metabolized 
in humans, and exhibited little or no capacity as a direct-
acting and/or irreversible metabolism-dependent inhibitor of 
P450 enzymes.16 It is therefore unlikely to affect compounds 
metabolized by this enzymatic system.
Efficacy studies
The use of biomarkers is one method of assessing the impact 
of antiresorptive therapy, with lower levels demonstrating 
decreased resorption and bone turnover. Such biomarkers 
Table 1 Key points of zoledronic acid
1.    Fracture prevention with oral bisphosphonates in PMO is limited 
by nonadherence, partly due to Gi intolerance, frequency of 
administration and inconvenience of dosing.
2.  For PMO, ZOL is administered annually as a 5 mg infusion.
3.    Efficacy of ZOL in PMO has been confirmed in the HORIZON PFT 
trial: 41% reduction in hip fractures, 70% reduction in morphometric 
vertebral fractures.
4.    ZOL is the only bisphosphonate that is associated with decreased 
mortality (post-hoc analysis) following hip fracture (HOriZON rFT).
5.    ZOL has a good safety profile. The most common side-effects are 
postinfusion flu-like symptoms, but these significantly diminish with 
successive infusions.
6.    66% to 79% of patients have expressed a preference for ZOL, 
including those with postinfusion symptoms.
7.   when administered, iv ZOL effectively guarantees adherence for 
12 months following infusion, and will therefore likely decrease frac-
ture rates in the “real-world” setting.
8.    Cost-effectiveness and head-to-head comparison with oral 
bisphosphonates are needed to fully elucidate the role of ZOL in PMO.
Abbreviations: PMO, postmenopausal osteoporosis; ZOL, zoledronic acid; 
HOriZON, Health Outcomes and reduced incidences with ZOL Once Yearly trial; 
PFT, Pivotal Fracture Trial; rFT, recurrent Fracture Trial; iv, intravenous.Patient Preference and Adherence 2009:3 191
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include urine N-telopeptide of type I collagen (NTX), serum 
β-C-telopeptide of type I collagen (β-CTX), and bone-specific 
alkaline phosphatise. When compared to weekly alendronate 
in a 24-week trial,13 ZOL showed faster reduction in 
mean urine NTX at 1 week, and greater reduction in NTX 
and β-CTX and at all follow-up points, implying faster and 
greater reduction in bone turnover.
The Health Outcomes and Reduced Incidences with ZOL 
Once Yearly (HORIZON) Pivotal Fracture Trial (PFT)17 was 
an international placebo-controlled randomized double-blind 
trial (n = 7736). It assessed the efficacy of 5 mg IV ZOL 
given annually for 3 years in reducing new vertebral and hip 
fractures. The patients were women aged 65 to 89 years with 
PMO. All patients received daily calcium (1000 to 1500 mg) 
and vitamin D (400 to 1200 IU). At 3 years, ZOL significantly 
reduced the relative risk of morphometric vertebral fracture 
by 70% (3.3% vs 10.9%, P  0.001), and hip fracture by 41% 
(1.4% vs 2.5%, P = 0.002). ZOL also significantly reduced 
the incidence of clinical vertebral fracture by 77% (0.5% vs 
2.6%, P  0.001), nonvertebral fractures by 25% (8.0% vs 
10.7%, P  0.001), and all clinical fractures by 33% (8.4% 
vs 12.8%, P  0.001). BMD at the total hip, lumbar spine and 
femoral neck were increased significantly, by 6.0%, 6.7%, 
and 5.1%, respectively, compared with placebo (P  0.001 
for all comparisons).
The subsequent HORIZON Recurrent Fracture Trial 
(RFT)18 examined the efficacy of ZOL in 2127 patients (24% 
men, 76% women) who had undergone surgical repair of a 
low-trauma hip fracture. Patients must have been unable or 
unwilling to take oral bisphosphonates and were randomized 
within 90 days of fracture to ZOL (n = 1065) or placebo 
(n = 1062). Median follow-up was 1.9 years. There were 
significant relative risk reductions in new clinical fractures 
(35%), clinical vertebral fractures (46%), and nonvertebral 
fractures (27%), and a nonsignificant 30% reduction in hip 
fractures (P = 0.18).
Of note, there have been no head-to-head clinical trials 
to date comparing the efficacy of different bisphosphonates 
with fracture as the primary endpoint.
Safety and tolerability
ZOL was well tolerated in the HORIZON PFT trial.17 The 
most common adverse events were postdose symptoms: 
pyrexia, myalgia, headache, arthralgia, or influenza-like 
symptoms. Any or a combination of these occurred primarily 
following the first infusion (31.6%). This progressively 
decreased with subsequent infusions to affect only 2.8% 
after the third infusion. Such symptoms can be mitigated 
with acetaminophen or ibuprofen before and after the first 
administration.18
As in some studies of other bisphosphonates, arrhythmias 
in the HORIZON PFT were significantly higher in the 
ZOL group (6.9% vs 5.3% placebo, P = 0.003), includ-
ing 50 patients with serious atrial fibrillation (AF) (1.3% 
vs 0.5% placebo, P  0.0001). Of these 50 patients, however, 
47 developed AF more than 30 days postinfusion. It must be 
noted that in patients who underwent electrocardiography, 
there was no difference in AF detection (2.1% vs 2.8% 
placebo). There was no difference in the occurrence of stroke 
(2.8% in both groups). ZOL did not increase cardiovascular 
mortality – there was no significant difference in death 
due to stroke (0.5% ZOL vs 0.3% placebo, P = 0.15), or 
cardiovascular causes (1.0% ZOL vs 0.9% placebo, P = 0.55). 
In the HORIZON RFT, there was no increase in the risk of 
AF (1.1% in the ZOL group vs 1.3% in the placebo group, 
P = 0.84). It is noteworthy that this study was conducted in 
the postoperative period, a time that usually confers increased 
risk of arrhythmias. The FDA continues to monitor data 
regarding atrial fibrillation, and has stated that “across all 
studies, no clear association between overall bisphospho-
nate exposure and the rate of serious or nonserious atrial 
fibrillation was observed. Increasing dose or duration of 
bisphosphonate therapy was also not associated with an 
increased rate of atrial fibrillation”.19 Consequently, the FDA 
has advised that healthcare professionals should not alter 
their prescribing patterns for bisphosphonates, and patients 
should not discontinue therapy for this concern.
As mentioned, ZOL is not recommended in those 
with creatinine clearance 30 mL/min, and patients with 
CrCl 30 mL/min were excluded from the HORIZON 
trial. A greater proportion of patients in the ZOL group 
had a transient increase in serum creatinine of more than 
0.5 mg/dL at 9 to 11 days postinfusion (1.2% vs 0.4% 
placebo, P = 0.001). By 30 days, however, 85% had returned 
to within 0.5 mg of preinfusion values, and the remainder had 
reverted to this range by the next annual follow-up.
In the HORIZON-RFT,18 ZOL was associated with a 
28% lower mortality risk compared to placebo infusions 
(P = 0.01). This was the first time such a benefit was dem-
onstrated for a PMO medication. The rates of renal and 
cardiovascular adverse events were similar to placebo.
All bisphosphonates carry the same FDA-mandated class 
warning regarding osteonecrosis of the jaw (ONJ), defined 
as oral exposed bone lesions not healing after 8 weeks 
from identification.20 There were no spontaneous reports 
of ONJ in the HORIZON-PFT or HORIZON-RFT trials. Patient Preference and Adherence 2009:3 192
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In HORIZON-PFT, one patient in each group had delayed 
wound healing classified as potential ONJ, but both cases 
resolved with antibiotics and limited debridement.
Patient preference
One can expect patient preference for therapies with 
extended dosing intervals, as demonstrated in several studies 
comparing daily, weekly and monthly oral bisphosphonates. 
In a recent double-blind, randomized, placebo-controlled 
trial assessing the safety and biomarker changes of weekly 
oral alendronate vs annual ZOL, 79% of patients preferred 
an annual infusion.14 Similarly, Saag et al reported that a 
majority of patients (66%), including those experiencing 
flu-like symptoms, expressed a preference for annual ZOL 
versus weekly alendronate.13
An earlier study showed that when given the hypothetical 
choice of PMO therapies, 65% of treatment-naïve patients 
with BMD-confirmed osteoporosis chose to receive an 
annual IV bisphosphonate infusion.21 Patients with a poorer 
perceived health status, high perceived risk of future fracture, 
and those preferring to manage their health without doctors, 
were more likely to choose an annual IV infusion. Patients 
unable to tolerate or properly take oral bisphosphonates were 
excluded from this study, to avoid bias towards IV therapy. 
Among those who were already on bisphosphonates, only 
a preference for prescription drugs predicted preference 
for oral therapy. The added benefit of recombinant human 
parathyroid hormone was not sufficient to overcome the 
dislike of daily subcutaneous injections.
Despite these studies demonstrating preference for annual 
ZOL, it is not known whether IV bisphosphonates improve 
long-term adherence beyond the initial infusion. The rate of 
return for a second infusion has not been established.
Conclusions
Despite proven efficacy, the clinical benefit of oral bisphos-
phonates is significantly limited by nonadherence to therapy. 
ZOL, by virtue of its intravenous administration, extended 
dosing interval, improved bioavailability, proven efficacy, 
and minimal side-effects, is an excellent option. Admittedly, 
there are no data on safety or sustained efficacy beyond 
3 years of therapy (the follow-up period in HORIZON). At 
this time, though, there is no reason to suspect that these 
would change. It is also not known whether the current annual 
5 mg IV regimen provides optimal efficacy.
As described, patients have expressed a strong 
preference for IV bisphosphonates in several studies. The 
effectively guaranteed 12 months of adherence following 
infusion distinguishes ZOL from other bisphosphonates, 
and will likely lead to decreased vertebral and nonvertebral 
fractures in the “real-world” setting. This will not only 
benefit PMO patients directly, but also lead to decreased 
fracture-related healthcare costs. Proper health-economic 
analysis will be needed to clarify this cost-effectiveness 
issue, however.
We believe that ZOL should be the therapy of choice 
in PMO patients for whom bisphosphonates are indicated, 
and who have a malabsorption syndrome, are intolerant of 
oral therapy, or are nonadherent (suspected or confirmed). 
Additional head-to-head comparisons with oral bisphospho-
nates, with fracture outcomes, are needed to fully elucidate 
the role of ZOL in the treatment of PMO.
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